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Objectives:  Centers  of  expertise  (CoE)  are vital  to  the  care  and  treatment  of  patients  with
rare diseases  and play a central  role  in  generating  medical  and  scientiﬁc  knowledge.  This
study  explores  the  relationship  between  a  CoEs  internal  resource  availability,  operational
experience  and  functional  network  integration  and  its  research  performance.
Method:  Hypotheses  were  tested  based on a  sample  of 64 CoEs  in  Europe  and  North  Amer-
ica that  specialize  in  6  rare  diseases.  We  collected  questionnaire  data  related  to  strategic
and structural  antecedents  and  subsequently  examined  bibliometric  data  in  the  ISI  Web  of
Science  database  to  determine  (1) research  output  by  publication  counts  and  (2)  research
impact  by the  number  of citations.
Results:  A  CoEs  research  performance  is  greatly  determined  by  available  experiences  and
internal  resources  as well  as  by  the  nature  of  networks.  While  research  output  increases
with  the  number  of  treated  patients,  the  amount  of resources  and  access  to  R&D  networks,
the impact  of  the  identiﬁed  publications  is  not  related  to a  CoEs  availability  of  internal
resources  or  to the  size  of  its  R&D  network.  Nevertheless,  a  CoEs  focus  on care-oriented
networks  increases  its  research  impact.
Conclusion:  Under  the  guidance  of different  national  efforts,  this  study  aims  to  support  a
nationwide  establishment  of specialized  CoEs  for rare  diseases.  It emphasizes  the relevance
of  CoEs  for the  generation  of  medical  knowledge  for rare  diseases  as  well  as  their  need  for
essential  support  through  internal  and  external  resources.  The  ﬁndings  further  show  the
necessity for  CoEs  not  only  to concentrate  on  R&D  collaborations  to generate  completely
new  knowledge  and  opportunities  but  also  to  establish  networks  with  operational  care  part-
ners such  as  general  practitioners,  local  therapists,  rehabilitation  centers  or  other  hospitals.
 . IntroductionOver the past few years, many voices have been raised
emanding the creation of centers for rare diseases in
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various health care systems to (1) bundle specialized
knowledge that meets ‘minimum volume’ regulations, (2)
enhance research activities and, consequently, (3) improve
medical outcomes and thus the long-term care of patients
living with a rare disease. Due to numerous inconsistent
and country-speciﬁc deﬁnitions of these centers, we use
Open access under CC BY-NC-ND license.the term ‘center of expertise’ (CoE) to represent spe-
cialized hospitals or ambulatory units for in-patient and
out-patient care that ensure reliable diagnosis, holistic
treatment and participation in research.
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Reﬂecting the efforts of different nations from Europe
and North America, such as the European Organization for
Rare Diseases (EURORDIS), the Nationales Aktionsbünd-
nis für Menschen mit  seltenen Erkrankungen (NAMSE), the
Rare Diseases Clinical Research Network (RDCRN) and the
Ofﬁce of Rare Diseases Research (ORDR) [1–4] in Europe
and North America, this study aims to support the estab-
lishment of specialized CoEs for rare diseases. CoEs may  be
an appropriate way to exploit limited medical and scientiﬁc
resources through a consistent and efﬁcient approach and
could equitably beneﬁt patients with rare diseases. In par-
ticular, different facets of coordination may  play important
roles to improve the quality of care: within and between
CoEs, between CoEs and primary care, between research
and care activities and between various services [1].  CoEs
integrate care by promoting collaboration and coordination
between various healthcare providers and sectors [5].  They
develop a provisional organization, provide expert advice
and ensure access to the most adequate treatment and
technologies [1].  Thus, the integration of care through CoEs
seeks to achieve coordinated care tailored to the patient’s
needs based on a holistic view of the patient [6].
In contrast to common diseases, rare diseases are
deﬁned by a prevalence of less than 5 in 10,000 patients;
however, as approximately 6000 different rare disease
patterns exist, they still have signiﬁcant epidemiological
relevance [7].  Rare diseases are often chronic, progressive,
degenerative and disabling, greatly affecting the quality of
life of patients. These diseases frequently affect multiple
organs, thus requiring complex and interdisciplinary treat-
ment. Due to the rarity of these diseases, a limited number
of patients and a scarcity of expertise severe knowledge
gaps and uncertainties affect medical care.
In order to generate essential new medical knowl-
edge to reduce uncertainties specialized centers for the
diagnosis and interdisciplinary treatment of rare diseases
may  be helpful [8].  A critical number of patients are
an indispensable condition for conducting research and
improving the scientiﬁc and medical knowledge of a
disease. However, in the case of rare diseases, this can only
be ensured through transnational and cross-institutional
cooperation, given the scarce number of patients within
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a single country [1].  To facilitate such cooperation, CoEs
have to develop networks and to create strategic alliances
beyond organizational boundaries [9],  including partners
from other medical domains. These networks may  help to
implement new knowledge in daily clinical processes. As
such CoEs for rare diseases have to balance exploitative
operational patient care and explorative research activities
by integrating research into daily clinical work.
Previous studies have already provided support for a
positive relationship between the proﬁciency of opera-
tional processes, research activities, performance mea-
sures, and patient outcomes [10–13].  Further the existing
literature has shown that an organization’s research per-
formance is driven by different individual, organizational
and network effects [14]. Thus, the purpose of our study
is to shed light speciﬁcally on the joint inﬂuence of opera-
tional experience, resource access and network integration
on the research performance of a CoEs. Thereby we focus
on six rare diseases with different prevalences (see Fig. 1).
Hence, we contribute to the discussion about what essen-
tial functions need to be met  by medical centers to create
and diffuse medical knowledge.
2. Theoretical framework and hypotheses
An organization’s explorative activities have a major
impact on its competitive advantage, particularly in
knowledge intensive and dynamic environments [14,15].
Research performance can be seen as a competitive advan-
tage also in the context of rare diseases, providing higher
quality of care and treatment through new scientiﬁc
knowledge. Therefore to investigate a CoEs research perfor-
mance as a central explorative performance outcome the
amount and the impact of created knowledge have to be
reﬂected.
The conceptual framework of this study is based on
the resource-based view, originally seen as theory of the
ﬁrm, to explaining performance [16]. Resources tradition-
ally refer to process or activity inputs on an organizational
level [16], which may  inﬂuence research performance as
an outcome variable. However, recent research shows
that individual and network level antecedents can also
Research performance
Research output
Research impact
ramework.
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nﬂuence the competitive advantage and organizational
erformance measures [14,15]. Consequently, we ﬁrst con-
ider internal resources for research provided by the CoE
s an organizational factor that inﬂuences research per-
ormance. Second, we draw upon the fact that relevant
esources can be found in the employees’ competencies
nd experiences as an accumulated individual operational
xperience of the CoE. Hence, an organization’s success
igniﬁcantly depends on its ability to build on internally
xisting knowledge, skills and experiences [17–19].  Finally,
etworks standing for external partnerships provide valu-
ble opportunities to access new knowledge that is also
ritical to developing innovative outcomes. Through a CoEs
etwork with different partners the institution is likely to
ccess desired strategic resources and external informa-
ion, both inﬂuencing its research performance [20].
CoEs face the challenge of fulﬁlling daily operational
are while investing in research to generate new scien-
iﬁc and medical knowledge. Hence, they must balance
wo different organizational foci, exploitation to maintain
hort-term operational success and exploration to support
esearch to ensure long-term performance [21–24].  Recent
esearch describes a kind of ambidextrous organization
hat is capable of doing both. However, the complexity of
ombining the exploitation of existing competencies with
he exploration of new opportunities requires adequate
rganizational support [25]. Support in this context refers
o the internal provision of resources for research in a CoE.
herefore, the more internal resources provided; the better
oEs can cope with the complexity, which can in turn lead
o an increase in research performance. The more fund-
ng, time and equipment that are provided for research, the
ore relevant scientiﬁc output may  be generated. Second,
ith more available research resources available, perfor-
ance in terms of impact and quality will be improved, as
he CoE is able to focus exclusively on the research task.
his leads to our ﬁrst set of hypotheses for this study:
ypothesis 1a. A CoEs internal access to resources posi-
ively inﬂuences its research output.
ypothesis 1b. A CoEs internal access to resources posi-
ively inﬂuences its research impact.
Aside from the organizational effect of internal
esource availability, a CoEs research performance may
lso be affected by its individual operational experience.
he need to achieve a critical number of patients is a nec-
ssary condition for improving the scientiﬁc and medical
nowledge about a disease [26]. Thus, operational medical
xperience in the daily care of rare diseases is essential
o detecting potential problems in diagnosis and therapy.
edical professionals will learn through observation, try
ew approaches and carry out clinical trials. Moreover,
perational experience supports a CoEs ability to concen-
rate scientiﬁcally on a certain rare disease as their main
esearch focus. Experience in this context is represented by
he number of patients treated in a particular institution
ver time. We  argue that a CoEs research performance
epends on its experience: the higher the number of
atients treated with a speciﬁc disease, the higher the
nternal existing knowledge, which positively inﬂuences Policy 105 (2012) 138– 145
the research performance in terms of output. Moreover,
the better the existing internal knowledge pool for a
certain rare disease is, the higher the scientiﬁc acceptance
of research results within the community.
Hypothesis 2a. A CoEs operational experience positively
inﬂuences its research output.
Hypothesis 2b. A CoEs operational experience positively
inﬂuences its research impact.
Regarding the network effects on research perfor-
mance, organizations may  interact with external partners
to leverage and access knowledge outside their bound-
aries. External cooperation is widely seen as a key concept
of knowledge creation and innovative performance [27].
The great beneﬁt of alliances lies in the complimentary
knowledge that can be accessed through different network
partners [28–30]. Furthermore, the partners may  exchange
personal, materials or devices that are necessary to perform
research tasks. As such, the access to external knowledge
and resources outside of one’s own  domain is essential
to generating new ideas and fostering an organization’s
explorative activities [20]. Eisenhardt and Martin even pos-
tulated a risk of obsolescence when organizations gain
all of their knowledge internally [14]. The act of building
alliances with different network partners facilitates learn-
ing by acquiring new knowledge and leveraging existing
knowledge and resources [31–33].
CoEs that engage in research and development-oriented
network partnerships will be better able to generate com-
pletely new knowledge. Thus, the better a CoE is integrated
into a research and development-oriented network, the
higher its research output. Furthermore, research and
development-oriented partnerships foster scientiﬁc accep-
tance through credibility and so may  improve a CoEs
research impact.
Hypothesis 3a. R&D network integration positively inﬂu-
ences a CoEs research output.
Hypothesis 3b. R&D network integration positively inﬂu-
ences a CoEs research impact.
More operationally oriented care networks will mainly
complement existing capabilities and value chains. There is
sufﬁcient evidence that cooperative relationships between
hospitals foster an efﬁcient use of resources in terms of
knowledge, thus helping to access further information
and complementary clinical expertise [31,34].  Healthcare
professionals integrated into those networks are able to
accumulate knowledge that guides them to adopt appro-
priate strategies for treatment and care [35]. They have
access to complementary clinical knowledge in the daily
care processes performed by external partners. Therefore,
CoEs integrated into rather large operational networks can
build upon a broader range of operational and care related
knowledge. By a broader range of operational knowledge,
we refer to the heterogeneity of cross-hierarchical and
cross-professional expertise to which a CoE has access
through its network. Exposure to heterogeneous opera-
tional knowledge is ﬁrst associated with the ability to
perform routine ongoing tasks, but simultaneously raises
the innovative performance [36]. Several studies [37,38]
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already suggest that knowledge heterogeneity in networks
contributes to innovative outcomes. Hence, we assume
that the integration of a CoE into an operational-oriented
network positively inﬂuences its research output. Further-
more, such networks ensure access to new patient groups
to increase patient numbers and facilitate the conduction
of clinical trials. In return, operational care network part-
ners can make use of a CoEs research results and ﬁndings
and thus support the increase of its research impact.
Hypothesis 4a. Care network integration positively inﬂu-
ences a CoEs research output.
Hypothesis 4b. Care network integration positively inﬂu-
ences a CoEs research impact.
3. Methods
This study focuses on six rare diseases that were
selected in order to reﬂect different levels of existing
knowledge due to differences in their prevalence. We  chose
the following diseases to test our theoretically derived
hypotheses: cystic ﬁbrosis (CF), amyotrophic lateral sclero-
sis (ALS), Marfan’s syndrome (MA), Wilson’s disease (MW),
epidermolysis bullosa (EB), and neurodegeneration with
brain iron accumulation (NBIA). The CoEs were identi-
ﬁed through local patient organizations and the database
orphanet [39]. A CoE in our sample was deﬁned as an insti-
tution employing its own staff, in most cases as part of a
larger hospital. In summary, 329 CoEs in 16 different coun-
tries in Europe and North America were contacted. Medical
management, medical staff and quality management were
asked to participate in the study and each of them – if
identiﬁed –, received a questionnaire. Participation was
voluntary and all information was kept conﬁdential as
assured by code numbers assigned to CoEs. Sixty-nine CoEs
indicated their support and returned the questionnaire,
producing an institutional response rate of 21%. Institutions
were distributed in accordance with the prevalence of each
investigated disease pattern: 37.5% CF, 25% ALS, 9.4% MA,
9.4% MW,  17.1% EB and 1.6% NBIA. After deleting incom-
plete questionnaires, the ﬁnal sample consisted of 64 CoEs,
22% from North America and 78% from Europe. In cases
of multiple responses for a CoE, data were aggregated by
a mean value on an organizational level. Mean size mea-
sured through the number of full-time employees was 8.7
and the CoEs showed a mean employee ﬂuctuation within
the last 5 years of 2.
To assess overall operational experience, participants
were asked to indicate the number of patients suffering
from a speciﬁc disease pattern treated by the CoE in 2005
and 2010. We  used a multi-year perspective to measure
its accumulated experience as a mean value of treated
patients with the disease per year. This absolute num-
ber of patients was then adjusted to hundred patients. To
gather information about access and provision of internal
resources, we ﬁrst started with a detailed literature review
of research articles dealing with exploitation and explo-
ration. We  screened the most stated factors for an adequate
organizational support to be able to act ambidextrous in
combining exploitation an exploration [25]. Afterwards we
transferred them from a more industrial related context Policy 105 (2012) 138– 145 141
to the given context of CoEs for rare diseases and ﬁnally
extracted ﬁve items measured with a ﬁve-point Likert
scale. Participants were asked which kind of resources are
provided for experts of a rare disease in the CoE: funding for
research, specialized staff supporting research activities,
administrative staff (e.g., study ofﬁce) supporting research,
enough time left for research activities and access to tech-
nological and laboratory equipment. The items loaded on
a single factor with an eigenvalue of 3.65, with factor
loadings from .77 to .89. The reliability of this scale was
 ˛ = .91. To assess the network integration,  participants were
asked how frequently the CoE interacts with certain part-
ners of both a more operationally oriented care network
and a more research and development-oriented network.
A list of 8 potential network partnerships was  provided
with general practitioners, local therapists, other hospitals
and rehabilitation centers representing the care network,
and with medical device or technology companies, phar-
maceutical companies, medical associations and research
institutions representing the R&D network. The results of
the factor analysis conﬁrmed the dichotomous network
classiﬁcation. The possible care network partners loaded
on one factor with an eigenvalue of 2.78 and factor load-
ings from .72 to .91 (reliability of  ˛ = .84). The possible
R&D network partners loaded on a second factor with
an eigenvalue of 2.00 and factor loadings from .57 to .77
(reliability of ˛ = .66). To reduce unobserved heterogeneity,
we controlled for a disease’s prevalence with the informa-
tion published in the database orphanet [39], representing
a given level of uncertainty due to the lack of medical
knowledge. The lower the prevalence, the more uncer-
tainty exists. Additionally, we  controlled for the type of the
medical center by coding a dummy  variable with the value
1 for academic medical centers and 0 for other medical
centers.
Although other indicators to evaluate research perfor-
mance may  be possible, e.g., inventions, patents or trials,
we focus on the publication performance. In the given con-
text of knowledge intensive healthcare services for rare
diseases, particularly the diffusion of created knowledge
by publications may  help to close severe knowledge gaps
and to abolish uncertainties. The number of publications
can be seen as a good indicator of the amount of cre-
ated knowledge while the number of citation reﬂects the
degree of diffusion. It is more valid to rely on a CoEs pub-
lication output than on patents or clinical trials. Patents
only cover technological knowledge and the latter only
reﬂect a vehicle to create knowledge rather the knowl-
edge itself. Furthermore national system regulations could
restrict the comparability of variables such as clinical trials.
To investigate a CoEs research performance, we distinguish
between the output and impact. According to Moed et al.,
research output is the extent to which a body of scien-
tiﬁc results is created [40]. The impact of publications is
deﬁned as the amount of inﬂuence the research output
has on other person’s activities [40]. Although numerous
publications are produced, only a few are accepted by the
scientiﬁc community and subsequently included in further
research and applications. Research impact is not exclu-
sively an indicator of quality; it also reﬂects the reputation
and related visibility of a CoE within the community and
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Table  1
Means, standard deviations and correlations.
Mean SD 1 2 3 4 5 6 7 8
1. Research output (log) .18 1.55
2. Research impact 3.85 3.71 .37**
3. Prevalence 18.62 16.02 .09 .03
4. Type of medical center .52 .50 .25* .24 −.20
5.  Research resources 2.92 1.16 .29* .01 .10 −.06
6.  Operational experience 1.30 1.28 .34** .28* .18 −.16 .18
7.  R&D network 8.89 4.39 .29* −.23 .01 .14 .26* −.01
8.  Care network 10.88 5.68 −.03 .28* −.12 .01 .19 −.12 .42**
N = 64; two-tailed.
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 CoEs efforts to transfer results. Therefore, we examined
esearch output in terms of quantity of publications and
esearch impact by number of citations. Bibliometric data
re seen as an objective quantitative indicator for scientiﬁc
erformance [41,42]. The data source used for this investi-
ation was the ISI Web  of Science database. We  chose this
atabase because it offers a cited reference index, which is
n appropriate tool for retrieving accurate citation counts.
e further cross-checked our results by comparing the
evealed WoS  data with the PubMed database. Relevant
ublications were identiﬁed by searching for articles with
he disease’s name in the title, abstract or keywords and the
oEs name in the authors’ address. Research performance
s represented by the use of the natural log of the number
f publications per year and per employee as a proxy for
esearch output as well as the average citations per pub-
ication as a proxy for research impact. This means that a
reater number of publications from a certain CoE indicate
igher research performance in terms of output. Citations
ndicate that other publications have made use of a certain
ublication; therefore, we used them as an indicator for the
mpact of the research [43]. We  limited our search to the 3
ears between 2009 and 2011 to reduce endogeneity prob-
ems. Altogether, we identiﬁed 1560 publications and 370
itations.
. Results
The purpose of this study was to reveal main predic-
ors of a CoEs research performance. Table 1 presents the
esults for means, standard deviations and correlations
or each variable considered including controls, predic-
ors and dependent variables. The correlation coefﬁcients
re low, especially considering the two control variables,
revalence and type of medical center. Academic medical
enters show a higher research output but the type of the
edical center does not correlate with research impact.
oreover, prevalence does not show any correlation with
ither research output or research impact, although one
ould assume that the higher the number of affected per-
ons, the stronger the research intensity in this ﬁeld would
e and hence, the higher the research output. However, our
tudy only includes rare diseases, while in comparison with
ther diseases effects may  be likely.
Before conducting multiple regression analysis, we
xamined residual plots, colinearity diagnostics andDurbin–Watson criterion to verify that regression assump-
tions were met. In this study, we  did not use a count data
model as we  calculated publications per year of existence
and per number of employees. We  applied ordinary least
square (OLS) modeling because it is a robust method in this
case where the data were almost normally distributed and
came from a small sample of only 64 CoEs. Our ﬁndings
show that our model is able to explain 32% of the variance
of a CoEs research output and 28% of the variance of a CoEs
research impact. First we introduced the block of control
variables into the equation, followed by the four different
independent predictor variables. Additionally to our tests
of linear effects of the independent variables, we also tested
curvilinear effects. However this additional test for did not
show any signiﬁcant quadratic effects.
In our tests for linear effects as shown in Table 2,
columns I and II, the type of CoE (i.e., if it is an academic
medical center) signiﬁcantly inﬂuences both research out-
put at the p = .008 level and research impact at the p = .009
level. This indicates a strong research orientation for aca-
demic medical centers. The prevalence of a disease is not
related to a CoEs research performance.
Within the derived framework, the ﬁrst set of hypothe-
ses proposed a positive relationship between research
output (1a) and research impact (1b) and the availability
of resources for research activities within a CoE. However,
our data only provide support for Hypothesis 1a at the
p = .004 level. The second set of hypotheses posited that
research output (2a) and research impact (2b) are posi-
tively associated with the degree of operational experience,
as represented by the number of patients suffering from
a speciﬁc rare disease treated in the multiyear period of
2005–2010. Our data support both assumptions (2a) at the
p = .003 level and (2b) at the p = .002 level. The third set of
hypotheses is also partially supported by the data from our
study. A higher level of integration in an R&D network was
signiﬁcantly related to research output (3a) at the p = .0215
level, but we had to reject Hypothesis 3b concerning the
relationship with research impact. Furthermore, the ﬁnal
hypotheses set 4 assumed a positive relationship between
research output (4a) and impact (4b) and integration into
an operationally oriented care network. As our data show,
we  could only conﬁrm Hypothesis 4b where integration of
a CoE into a care network positively inﬂuences its research
impact at the p = .01 level. For a detailed summary of all
regression results, see Table 2.
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Table  2
Regression analysis results.
Dependent Research output Research impact
Model 1a Model 1b Model 2a Model 2b
Intercept −.50 (.38) −2.10 (.63)** 2.54 (.91)** −6.2 (1.55)
Prevalence .01 (.01) .00 (.01) .02 (.03) .02 (.03)
Type  of medical center .84 (.38)** .88 (.35)** 1.90 (.93)** 2.14 (.86)**
Research resources H1a + 1b .29 (.15)* −.42 (.38)
Operational experience H2a + 2b .30 (.10)** 1.60 (.90)**
R&D network H3a + 3b .09 (.04)* .09 (.11)
Care  network H4a + 4b −.04 (.03) .20 (.08)*
F 1.51 1.34 3.65 3.31
F  2.64* 5.14*** 2.11 4.28**
R2 .08 .24 .06 .22
R2 .08 .32 .06 .28
Unstandardized b; standard error; N = 64; one-tailed tests.
* p < .05.
** p < .01.
*** p < .001.
5. Discussion
This paper analyzed the relationship between a CoEs
access to internal resources, its operational experience
with one speciﬁc rare disease pattern and its network
integration with either R&D or operational care partners,
and its overall research performance. In particular, this
paper highlights the main parameters fostering research
performance of CoEs for rare diseases. In this context,
research performance has to be differentiated between
output and impact, meaning the quantity of publica-
tions on the one hand, and the diffusion of scientiﬁc
research results on the other. We  theoretically derived
hypotheses based on innovation and network literature.
To avoid common source bias, we tested the hypothe-
ses by combining self-reported measures with objective
bibliometric data to predict the research performance of
CoEs.
Our results show that academic medical centers, when
compared to general medical centers, are characterized
by a noticeably higher publication output. The reason is
unsurprising, as it is a well-known fact that physicians in
academic medical centers are strongly impelled to publish
[44]. With respect to the direct relationships, our regres-
sion results underline the vital importance of internal
resources for research output. Access to sufﬁcient fund-
ing, time, equipment and research services is essential
and should be considered when setting up CoEs for rare
diseases. However, resource access and provision are not
sufﬁcient determinants of the impact of research activi-
ties. This may  be due to the fact that an institution may
be able to control the number of its publications through
an appropriate resource provision, but it cannot control
the acceptance of its research within the scientiﬁc and
medical community. Furthermore, our results reveal the
central role of operational experience. Healthcare pro-
fessionals may  transform their experiences not only into
efﬁciency and efﬁcacy gains [45] but also into new knowl-
edge, which is reﬂected by a higher number of publications
and an enhanced scientiﬁc acceptance. Thus, the access to a
sufﬁcient number of patients is a sine qua non for perform-
ing clinical trials, which are the core vehicles for clinicalresearch. The network integration of CoEs for research
and care processes shows different effects on research
performance. Alliances with more R&D-oriented network
partners are positively associated with research output
but unrelated to research impact. In contrast, integration
into a more operational-care-oriented network is posi-
tively associated with research impact but unrelated to
research output. This is a particularly thought-provoking
ﬁnding. One could conclude that an R&D-oriented net-
work strengthens the amount of research output as they
provide human resources and complimentary knowledge
to produce scientiﬁc publications. However, on average
the publications may  be not more valuable for other col-
leagues in this medical ﬁeld. A main reason may  be seen
in the aspect that CoEs with a strong R&D network may be
rather basic research oriented. Among them genetic stud-
ies play a bigger role for rare diseases, which in turn show
a limited practical relevance for broader groups of clini-
cians. On the other hand, stronger ties with operational
partners show a contrary picture, in that such ties facili-
tate the diffusion of generated knowledge, resulting in a
higher number of citations per article and an increase in
the adoption and acceptance of new scientiﬁc knowledge.
However, as these partners are strongly involved in opera-
tional medical processes, they cannot help to increase the
number of publications because of existing time restric-
tions; hence, both network types seem to be important.
Furthermore one should take into account that besides
the underlining arguments for the positive effect of care
networks on research impact, other forms of transfer of
scientiﬁc results may  be relevant as well. Particularly train-
ings, seminars and conferences are typical instruments to
spread scientiﬁc knowledge. Hence, beside the cooperation
with care-related network partners, CoEs should also con-
centrate on the diffusion of their specialized knowledge
through other channels to make it generally available in
the wider region.
In summary, CoEs have to balance their network
integration, concentrating on both exploiting existing
knowledge and exploring completely new opportunities
[34]. Previous research also supports our general results,
reporting that the locus of innovation, and thus of research
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erformance, is to be found within networks of inter-
rganizational relationships.
Research performance in terms of publications and
ts scientiﬁc impact is a very sensitive outcome vari-
ble depending on various individual, organizational and
etwork factors. Our study accounts for a number of sig-
iﬁcant results across the three investigated antecedents of
esearch performance with a reasonable share of explained
ariance. This paper thus provides valuable suggestions
or the set-up of strategic and structural antecedents of
esearch performance. In contrast to common diseases,
ach of the three variable sets covering resource access,
perational experience and network integration are more
ritical in the ﬁeld of rare diseases. In particular the results
how that besides internal and external research ori-
nted resources also operational aspects, as experiences
nd care networks, are important antecedents of research
erformance. The balance between an exploitative and
xplorative strategic orientation of CoEs needs to become
n integral part of hospital management.
However, the present study does have a number of limi-
ations that need to be considered. First, the cross-sectional
ature may  lead to possible endogeneity problems and
eversed causalities. We  rely on outcome measure from
009 to 2011 and survey data from 2010. While we  believe
hat the institutional research performance is rather stabile
ver time, only a longitudinal study design could provide
dditional empirical evidence. This study also does not fully
ddress research quality, as research impact measured by
itation counts only provides some insight into the qual-
ty and diffusion of generated knowledge. Future research
ould therefore extend our ﬁndings by incorporating a
uality assessment, measuring the effect of the generated
nowledge on medical and patient outcomes. Moreover,
esearch in the context of rare diseases is heterogeneous.
 CoEs publications can also be classiﬁed in terms of sci-
ntiﬁc categories such as clinical processes, biochemistry,
enetics, medical laboratory technology and pharmacol-
gy. This raises the question as to whether resource access,
perational experience and network integration are dif-
erentially associated with research performance in these
cientiﬁc categories. Future attempts should also integrate
he patients themselves as potential network partners,
hich may  provide an additional and efﬁcient way to
trengthen research in the ﬁeld of rare diseases. The access
o and the availability of medical information on the
nternet combined with the ability to interact with other
atients through online or local communities has made
atients become experts in their own disease. Patients are
herefore another valuable source for the generation of
nowledge through networks.
. Conclusion
The healthcare of rare diseases requires a concentration
f the scarce expertise and resources. Thus, the aggrega-
ion of expertise through CoEs represents a very efﬁcient
ay to provide access to correct diagnosis and therapies
nsuring high quality healthcare particularly for rare dis-
ases. The establishment of CoEs as centralized in-patient
nd out-patient institutions for rare diseases represents Policy 105 (2012) 138– 145
not only an appropriate opportunity to exploit limited
medical resources through a consistent approach, but also
serves as a driver for the generation of needed scien-
tiﬁc knowledge for the beneﬁt of patients diagnosed with
rare diseases. The dissemination and diffusion of new
knowledge is a central condition to be fulﬁlled by those
specialized institutions to ensure the widespread use of
knowledge and expertise across regions. CoEs add value
by bringing together expert operational experience, inter-
nal research resources and access to different and valuable
network partners. CoEs should create a research organiza-
tion to ensure the integration of more explorative activities
in daily clinical processes while increasing the proﬁciency
of research activities through a professional funding ofﬁce
and necessary support facilities. They also should foster
cross-institutional and cross-disciplinary training activi-
ties to build and harmonize standard operating processes
and the dissemination of operational guidelines [1].
Policy-level responses are required to adequately stim-
ulate and support the explorative role of CoEs. Hence,
health policy should provide support for developing and
maintaining intra-institutional cooperation and partner-
ships, e.g., with pharmaceutical companies, other research
institutions or medical device or technology companies,
to support extensive research activities. Shared research
resources are a second essential requirement, which should
be provided through policy regulations. Consequently,
health policy should consider (1) potential ‘minimum
volume’ regulations to increase patient numbers (the appli-
cability of ‘minimum volume’ regulations to rare diseases
currently causes a vivid discussion in health policy in
Europe and North America [46–50])  and (2) attempts
for the establishment of super-ordinate European and US
research networks for rare diseases. The constitution of
specialized centers for each of the existing 6000 rare dis-
ease patterns solely in each state would severely exceed
the ﬁnancial, medical and human resources. Thus, in addi-
tion to supporting CoEs, the establishment of transnational
networks including central registries and databases may  be
an appropriate way  to maximize quality healthcare provi-
sion and research outcome. (3) CoEs should develop and
maintain various ties with operational networks, which in
turn should be support by health policy agencies. (4) Met-
rics for the evaluation of CoEs should also include research
outcomes. Only if knowledge generation and dissemination
is considered, the outcomes of centralizing and interlink-
ing the diagnosis and treatment of rare disease can be fully
understood. Medical centers must combine operational
care with explorative activities in order to be considered
as a Center of Expertise.
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